Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5752W HIGH $2.44
Volume
28.00 K
Value Traded
187.07 K
Short % Float
0.39%
0%Week
+1.53%1 Month
-18.9%3 Month
+85.86%6 Month
-99.87%5 Year
-99.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.31 M
EPS (TTM)
-2.29
P/E Ratio
-
Ent. Value
5.07 M
Total Shares
5.49 M
Float Shares
4.08 M
Insiders
25.81%
Institutions
36.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INM Catalyst Timeline
Dated clinical, regulatory and corporate events for InMed Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for InMed Pharmaceuticals Inc.
326Total events
19Upcoming
44Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCINM-901Preclinical
Preclinical data demonstrating INM-901 reduces neuroinflammation in 3D human brain organoid models
Alzheimer's diseasesource ↗
●Corporate ApprovalCorporate
InMed filed Form S-4 registration statement with SEC for the Merger
▼Program DiscontinuationCorporate
Decision made to discontinue operations of BayMedica subsidiary
●IND SubmissionMT-001IND
First-in-human regulatory filing for MT-001 expected mid-2026
migraine preventionsource ↗
●IND SubmissionMT-001IND
First-in-human regulatory filing for MT-001 (anti-PACAP)
migraine preventionsource ↗
▲Preclinical PoCINM-901Preclinical
Positive data from human brain organoid neuroinflammation models supporting INM-901
Alzheimer's diseasesource ↗
▼Program DiscontinuationCorporate
Board ratified decision to wind down BayMedica commercial operations
●Quarterly UpdateCorporate
Reported Q2 fiscal 2026 financial results for period ended December 31, 2025
●Quarterly UpdateCorporate
2025 Annual General and Special Meeting held and results announced
▲Preclinical PoCINM-901Preclinical
Successful completion of PK studies in large animal model for INM-901
Alzheimer's diseasesource ↗
●IND Enabling CompleteINM-901Preclinical
Completed CMC development to scale manufacturing for IND-enabling studies
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-901Preclinical
Completed pharmacokinetic studies in large animal models for INM-901 oral formulation
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-901Preclinical
INM-901 demonstrated statistically significant reductions in key neuroinflammation signals in preclinical studies
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-089Preclinical
INM-089 demonstrated significant functional and pathological improvements in dry AMD model
dry age-related macular degenerationsource ↗
◆Oral PresentationPresentation
Corporate presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Poster PresentationINM-901Presentation
Presentation of INM-901 preclinical data at AAIC 2025
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-901Preclinical
Positive long-term in vivo preclinical AD data for INM-901
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-089Preclinical
Preclinical studies of INM-089 demonstrated functional and pathological improvements in dry AMD model
dry age-related macular degenerationsource ↗
▲Preclinical PoCINM-901Preclinical
Positive results from long-term in vivo preclinical AD study for INM-901
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-089Preclinical
Selection of intravitreal formulation for INM-089
dry Age-related Macular Degenerationsource ↗
◆Additional DataINM-901Clinical Data
Further molecular analyses and additional parameters from INM-901 study expected
Alzheimer's diseasesource ↗
▲Preclinical PoCINM-089Preclinical
Selection of intravitreal formulation for INM-089
dry age-related macular degenerationsource ↗
▲Patent GrantedIP / Competition
Patent granted in Mexico for cannabinoid analogs and methods of preparation
◆Full ResultsINM-901Clinical Data
Recent data from INM-901 presented at AAIC 2025
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How INM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | MT-001 (anti-PACAP monoclonal antibody) | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F14 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 99%
Micro Cap(rank 651 of 658)
Percentile Rank
InMed Pharmaceuticals Inc. has significant pipeline risk (14/100), with $39M risk-adjusted pipeline value, led by INM-755 in Epidermolysis Bullosa Simplex (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INM-755 Small moleculeCompletedNCT04908215 | Epidermolysis Bullosa Simplex | Phase 2 | COMPLETED | 19 | Apr 19, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every INM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| INM-755 | epidermolysis bullosa | Phase 2 | 2023-11-02 | positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream aloneRead More | NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC10% Owner | Buy | 2,256 945,924 held | $1.33 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 0.1 % | 1.24 M | 798.38 K |
INM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INM ranks across every disease it competes in
Competitive Position is a premium feature
See how INM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINM News
INMInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
InMed Pharmaceuticals has received a notification from Nasdaq regarding its non-compliance with the minimum shareholders' equity requirement. The company's equity is reported at $1,075,007, below the $2,500,000 threshold. InMed expects to regain compliance following a merger with Mentari Therapeutics, which is projected to provide significant funding. The company has 45 days to submit a compliance plan to Nasdaq.
Read more →INMInMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
InMed Pharmaceuticals reported its fiscal year 2026 financial results, highlighting a net loss of $12.9 million. The company is progressing towards a merger with Mentari Therapeutics, which is expected to enhance its financial position with a combined cash runway into 2029. InMed is also focusing on maximizing the potential of its legacy drug programs while navigating the complexities of the merger process.
Read more →INMInMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
InMed Pharmaceuticals Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, as it maintained a closing bid price above $1.00 per share for 10 consecutive business days. This follows a notification from Nasdaq concerning non-compliance on March 27, 2026. The company was informed on June 3, 2026, that the compliance issue is now resolved. InMed focuses on developing small molecule drug candidates for various therapeutic indications including Alzheimer's and dermatological conditions.
Read more →INM▲ +135.1%on this news
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
InMed Pharmaceuticals has announced a merger with Mentari Therapeutics to advance migraine prevention therapies. The merger combines Mentari's innovative migraine pipeline with InMed's public market infrastructure, aiming to expedite the development of new treatments. A concurrent $290 million private placement is expected to fund operations through 2028, with regulatory filings for new therapies anticipated in mid-2026 and early 2027.
Read more →INM▲ +135.1%on this news
InMed Pharmaceuticals Amends Preferred Investment Options
InMed Pharmaceuticals has amended the exercise price of certain preferred investment options held by Armistice Capital from $16.60 to $0.80. This change may enhance the likelihood of investment by Armistice. The company is focused on developing small molecule drug candidates targeting high unmet medical needs, particularly in Alzheimer's and dermatological conditions.
Read more →INMInMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals has reported its financial results for the third quarter of fiscal 2026, concluding with a net loss of $3.0 million. The report highlighted significant preclinical advancements for INM-901, targeting neuroinflammation related to Alzheimer's disease, showcasing substantial reductions in inflammatory markers across human brain organoid models. Despite the promising development, the company announced the discontinuation of its commercial operations, which could impact revenue as resources are redirected to enhance its drug development efforts. Overall, while there are advancements, the financial losses remain a concern as the company transitions focus areas.
Read more →INM▼ -5%on this news
InMed Pharmaceuticals Amends Preferred Investment
InMed Pharmaceuticals has announced amendments to its preferred investment options with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co. The exercise prices for these options are adjusted to $0.80. The amendments come as part of the company's strategy to strengthen its financial position while focused on its pipeline of small molecule drug candidates targeting various medical conditions.
Read more →INMInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
InMed Pharmaceuticals has received a notice from Nasdaq stating that its common shares have not met the minimum bid price requirement of $1.00 per share for continued listing. The company has a period of 180 calendar days to rectify this situation and may consider options like a reverse stock split. Failure to comply may result in delisting from Nasdaq, though there's a possibility of an additional grace period if certain conditions are met. InMed is focused on developing small-molecule drug candidates aimed at CB1/CB2 receptors, with programs targeting Alzheimer's and other conditions.
Read more →INM▼ -6.9%on this news
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901
InMed Pharmaceuticals has announced promising preclinical data demonstrating the efficacy of its drug candidate INM-901 in reducing neuroinflammation in human brain organoid models relevant to Alzheimer's disease. This new data showcases consistent anti-inflammatory effects that align with previous results from animal studies, suggesting the drug's potential translational value for human clinical applications. The organization plans to engage in regulatory discussions and aims to initiate Phase 1 clinical trials in 2027, marking significant progress in the development of treatments targeting neuroinflammation in Alzheimer's disease.
Read more →INMInMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
InMed Pharmaceuticals has announced advancements in its drug development programs, particularly for INM-901, aimed at treating Alzheimer's disease. The company plans to conduct a pre-IND meeting with the FDA in Q3 2026, targeting IND submission and a Phase 1 clinical trial initiation in 2027. Preclinical data supports INM-901's efficacy in reducing neuroinflammation and promoting neuronal health, positioning it favorably in the Alzheimer's treatment landscape.
Read more →INMInMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
InMed Pharmaceuticals has provided an update on its drug development programs, focusing on promising progress with INM-901 aimed at treating Alzheimer's disease. The company plans to hold a pre-IND meeting with the FDA in Q3 2026, paving the way for an IND submission and Phase 1 clinical trial expected to start in 2027. INM-901 has demonstrated substantial efficacy in reducing neuroinflammation and improving key biomarkers in preclinical studies. Additionally, InMed is progressing on INM-089 for treating dry age-related macular degeneration and plans to meet with the FDA in Q4 2026.
Read more →INMPro Forma Information on Continuing Operations The following unaudited pro forma consolidated financial information of InMed Pharmaceuticals Inc. (the "Company") is derived from its historical consolidated financial stat
InMed Pharmaceuticals Inc. released unaudited pro forma consolidated financial information reflecting the wind down of BayMedica LLC's commercial operations as discontinued operations. The statements for the six months ending December 31, 2025, and the year ending June 30, 2025, present estimated adjustments based on management's assumptions. These pro forma statements are for informational purposes only and do not guarantee future results. The company has not finalized fair value assessments of its assets related to the discontinued operations.
Read more →INMInMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal 2026, indicating steady progress in its drug development pipeline, particularly with INM-901 targeting neuroinflammation in Alzheimer's disease. Positive preclinical data support the advancement to human clinical trials. However, revenues from the subsidiary BayMedica decreased by 26% due to pending U.S. legislation which may adversely affect its commercial business. The company remains focused on pursuing pre-IND meetings with the FDA for both its INM-901 and INM-089 drug candidates.
Read more →INM▼ -8.7%on this news
InMed Announces Results of 2025 Annual General and Special Meeting
InMed Pharmaceuticals confirmed the results of its 2025 Annual General and Special Meeting held on December 17, where significant matters were voted on by shareholders. The election of the Board of Directors received favorable votes, with all nominated individuals receiving over 81% support. Additionally, shareholders approved the selection of CBIZ CPAs P.C. as auditors and the potential issuance of new shares under an equity agreement. Overall, the meeting reflects positive shareholder engagement and future corporate governance commitments.
Read more →INMInMed Provides Update on BayMedica Commercial
InMed Pharmaceuticals announced that the recently signed H.R. 5371 Act could significantly impact its subsidiary BayMedica’s commercial business. If implemented as currently drafted, aspects of BayMedica's cannabinoid inventory would become prohibited in November 2026. Despite this, InMed remains committed to its core pharmaceutical development programs, particularly in treating Alzheimer's and age-related macular degeneration. The company is exploring alternative supply chain options to ensure compliance with the new legislation.
Read more →INM▼ -11.5%on this news· ran to -27% by day 3
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for its Alzheimer's Disease Candidate INM-901
InMed Pharmaceuticals has successfully completed pharmacokinetic studies of its Alzheimer's disease candidate INM-901 in large animal models. The studies indicated robust bioavailability and supportive safety data, guiding the design for upcoming human clinical trials. The company has also progressed in chemistry, manufacturing, and controls development for INM-901, preparing for Investigational New Drug-enabling studies with the FDA. Overall, the results suggest a positive trajectory for InMed's Alzheimer's program.
Read more →INM▼ -5.5%on this news
InMed Pharmaceuticals Appoints Mr. John Bathery to Board of Directors
InMed Pharmaceuticals has appointed John Bathery to its Board of Directors, effective immediately. Bathery, who has over 30 years of experience in the pharmaceutical industry, will play a crucial role in advancing InMed's development programs, specifically in Alzheimer's disease and Age-Related Macular Degeneration. His expertise in corporate development and strategic partnerships is expected to greatly benefit the company's pipeline and potential collaborations. The announcement reflects InMed's strategic focus on growth and innovation.
Read more →INMInMed Pharmaceuticals Appoints Mr. Neil Klompas to it's Board of Directors
InMed Pharmaceuticals has appointed Mr. Neil Klompas to its Board of Directors, effective immediately. Klompas brings over 30 years of experience in healthcare and biotechnology, significantly contributing to Zymeworks' growth as a multi-billion-dollar company. He expressed enthusiasm for joining InMed, particularly regarding the promising data for INM-901, aimed at treating Alzheimer's disease. The board believes his expertise will be crucial as InMed progresses its development programs.
Read more →About InMed Pharmaceuticals Inc.
HeadquartersC/O NORTON ROSE FULBRIGHT CANADA LLP, VANCOUVER, V6B 0M3
BIOPHARMAWATCH ELITE PLUS
Trade the next INM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime